- $141.30m
- $134.93m
- $7.14m
- 46
- 32
- 93
- 58
Annual cashflow statement for CervoMed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -11.8 | -14.2 | -24.1 | -15.6 | -2.17 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.516 | 0.736 | 9.59 | 0.719 | -5.02 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.994 | 1.47 | 0.356 | -0.097 | -0.261 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -9.86 | -13.6 | -14.5 | -15 | -7.45 |
| Other Investing Cash Flow Items | — | — | 0.004 | -12.2 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | — | — | 0.004 | -12.2 | — |
| Financing Cash Flow Items | -0.163 | -0.982 | 0 | — | 10.3 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 16 | 17.9 | 33.3 | 0.005 | 11.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 6.19 | 4.34 | 18.8 | -27.2 | 3.7 |